ACER1 and central nervous system cancer: When we assessed the expression of available ceramidases (ACER1 was unavailable) in primary and recurrent gliomas using the Chinese Glioma Genome Atlas (CGGA) [16], we found that only ASAH1 was increased in recurrent gliomas while the other ceramidases were unchanged (Fig. 1A, S1C–E).